Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer

PURPOSE: Veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase 1 trial. To define the relative contribution of PARP inhibition to the observed clinical activity, we cond...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Kummar, Shivaani, Oza, Amit M., Fleming, Gini F., Sullivan, Daniel M., Gandara, David R., Naughton, Michael J., Villalona-Calero, Miguel A., Morgan, Robert J., Szabo, Peter M., Youn, Ahrim, Chen, Alice P., Ji, Jiuping, Allen, Deborah E., Lih, Chih-Jian, Mehaffey, Michele G., Walsh, William D., McGregor, Paul M., Steinberg, Seth M., Williams, Paul M., Kinders, Robert J., Conley, Barbara A., Simon, Richard M., Doroshow, James H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4383665/
https://ncbi.nlm.nih.gov/pubmed/25589624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2565
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak